Home/Companies/CIK 0000003116
A
ISSUER//CIK 0000003116

AKORN INC

Exchange

Entity type

operating

Fiscal year end

Dec 31

Headquarters

LA

Research Summary

AI-assisted · Grounded in filings

Updated Nov 28, 2025

AKORN INC

Akorn Inc was a generic pharmaceutical manufacturer specializing in alternate dosage forms including ophthalmics, injectables, oral liquids, otics, and nasal sprays for both human and animal health markets. The Lake Forest, Illinois-based company, with CIK 3116, marketed branded and generic prescription drugs targeting healthcare providers and consumers seeking affordable medication options. Material risks included regulatory compliance challenges, as evidenced by a $7.9 million settlement with the DOJ for fraudulent billing practices, and manufacturing quality control issues that contributed to significant operational difficulties. The company faced mounting financial pressures and ultimately filed for Chapter 7 bankruptcy in February 2023 after unsuccessful restructuring efforts. View detailed SEC filings and financial reports for Akorn Inc on Earnings Feed.